This protocol applies to patients with metastatic or advanced undifferentiated pleomorphic sarcoma (UPS) — the setting in which systemic chemotherapy is the primary treatment consideration.
In the metastatic or advanced setting, first-line treatment centres on doxorubicin-based chemotherapy. The protocol specifies whether doxorubicin is used alone or within a combination regimen, along with the clinical criteria guiding that choice — details available in the full structured protocol.
DOI: 10.1200/JCO.2017.
In the metastatic setting, doxorubicin as a single agent or in combination with ifosfamide or olaratumab is likely to be the first choice of chemotherapy, which assumes that the findings with these treatments in other STSs also are applicable to UPS.
View source ↗